NCT00611351 - Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 7, 2005

Primary Completion Date

February 1, 2008

Study Completion Date

September 17, 2008

Conditions

Graft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesSecondary Myelofibrosis

Interventions

BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

mycophenolate mofetil

DRUG

tacrolimus

GENETIC

polymerase chain reaction

GENETIC

polymorphism analysis

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

OTHER

pharmacogenomic studies

OTHER

pharmacological study

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

68198

Unversity of Nebraska Medical Center, Omaha

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER